Author

Whitney Handy

Observed names: W. Handy, Whitney F. Handy

Institution: Bristol-Myers Squibb (United States)

Observed institutions: Merck & Co., Inc., Rahway, NJ, USA (United States), Shenandoah University, Harris Health System, Bristol-Myers Squibb (United States)

OpenAlex ID: A5033045271

Suppression of collagen IV alpha‐2 subunit by prolyl hydroxylase domain inhibition via hypoxia‐inducible factor‐1 in chronic kidney disease

2021 · Mohammad Sanaei‐Ardekani, Shyreen Kamal, et al. · Pharmacology Research & Perspectives · 11

A Phase 1 Study to Evaluate the Pharmacokinetic Drug‐Drug Interaction Between Islatravir and Methadone in Participants on Stable Methadone Therapy

2024 · Randolph P. Matthews, Wendy Ankrom, et al. · Clinical Pharmacology in Drug Development · 1

Examining HSD3B1 as a possible biomarker to detect prostate cancer patients who are likely to progress on ADT

2020 · Whitney F. Handy, Keith T. Schmidt, et al. · Cancer Biology & Therapy · 1

Tolérance et efficacité du zola-cel, une thérapie par cellules CAR T ciblant le CD19, dans le lupus érythémateux systémique (LES) sévère et réfractaire : mise à jour de l’étude Breakfree-1

2026 · D. Simon, M. Wiesendanger, et al. · La Revue de Médecine Interne

OC.57 Safety and efficacy of CD19 NEX-T® (BMS-986353), a chimeric antigen receptor (CAR) T cell therapy, in systemic sclerosis (SSc): findings from the breakfree-1 trial

2026 · Dinesh Khanna, David S Korman, et al.

S15:01 Safety and efficacy of CD19 NEX-T® (BMS-986353)—a CD19-directed chimeric antigen receptor (CAR) T cell therapy—for severe refractory systemic lupus erythematosus (SLE): breakfree-1 trial update

2026 · David Simon, Margrit Wiesendanger, et al. · Oral Presentations

246: Validation of a pre-delivery risk stratification system for postpartum hemorrhage

2018 · Catherine S. Eppes, Kathleen Mundy, et al. · American Journal of Obstetrics and Gynecology

Works count: 7

Citation count: 13

H-index: 1

I10-index: 1